<DOC>
	<DOCNO>NCT01819129</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The aim trial compare FIAsp ( faster-acting insulin aspart ) insulin aspart , combination insulin glargine metformin adult type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety FIAsp Compared Insulin Aspart Combination With Insulin Glargine Metformin Adults With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) 6 month long time screen ( visit 1 ) Treated basal insulin least 6 month prior screen ( visit 1 ) Current daily treatment insulin NPH ( Neutral Protamine Hagedorn ) , insulin detemir glargine least 3 month prior screen visit ( visit 1 ) Current treatment : a. metformin unchanged dose least 3 month prior screen ( visit 1 ) . The metformin dose must least 1000 mg b. metformin combination sulfonylurea ( SU ) glinide DPPIV ( dipeptidyl peptidase4 ) inhibitor and/or alphaglucosidase inhibitor ( AGI ) unchanged dose least 3 month prior screen ( visit 1 ) . The metformin dose must least 1000 mg HbA1c central laboratory : . 7.0 9.5 % ( 53 80 mmol/mol ) ( inclusive ) metformin group screen visit ( visit 1 ) b . 7.0 9.0 % ( 53 75 mmol/mol ) ( inclusive ) metformin + OAD ( oral antidiabetic drug ) ( SU , glinide , DDPIV inhibitor , AGI ) combination group screen visit ( visit 1 ) Body mass index ( BMI ) equal 40.0 kg/m^2 Any use bolus insulin , except shortterm use due intermittent illness ( long 14 day consecutive treatment ) 3 month prior screen visit ( visit 1 ) Use GLP1 ( glucagonlike peptide1 ) agonists and/or TZDs within last 3 month prior screen ( visit 1 ) Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator hospitalisation diabetic ketoacidosis previous 6 month prior screen ( visit 1 ) Cardiovascular disease , within last 6 month prior screen ( visit 1 ) , define : stroke , decompensated heart failure New York Heart Association ( NYHA ) class III IV , myocardial infarction , unstable angina pectoris coronary arterial bypass graft angioplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>